While Amazon’s Big Spring sale officially ended on Monday, it seems the retailer has almost forgotten to end some of its best deals from the event – including on TVs, vacuums, kitchen appliances and own-brand devices. As a deals editor for TechRadar, I’ve gone through the left-over offers and hand-picked the 19 best deals I’d add to my cart.
I would add these deals to my cart because they represent outstanding value with record-low prices and rare discounts that you won’t find outside of big holiday sales. Some of my favorite bargains include the highly-rated Sony WH-1000XM4 headphones on sale for $248, the best-selling Bissell CleanView vacuum marked down to $69.99 and last but not least; a free Samsung 65-inch 4K TV when you purchase a new 2024 display.
Shop more of my top picks below and keep in mind that these are limited-time offers that Amazon could end at any moment. The next big holiday sale is Memorial Day, so you should grab these deals now before it’s too late.
T cells (pink) attack a cancer cell (yellow) in this scanning electron micrograph image.Credit: Steve Gschmeissner/SPL
A small Indian biotechnology company is producing a home-grown version of a cutting-edge cancer treatment known as chimeric antigen receptor (CAR) T-cell therapy that was pioneered in the United States. CAR-T therapies are used mainly to treat blood cancers and have burgeoned in the past few years. The Indian CAR-T therapy costs one-tenth that of comparable commercial products available globally.
A single treatment of NexCAR19, manufactured by Mumbai-based ImmunoACT, costs between US$30,000 and $40,000. The first CAR-T therapy was approved in the United States in 2017, and commercial CAR-T therapies currently cost between $370,000 and $530,000, not including hospital fees and drugs to treat side effects. These treatments have also shown promise in treating autoimmune diseases and brain cancer.
India’s drug regulator approved NexCAR19 for therapeutic use in India in October. By December, ImmunoACT was administering the therapy to paying patients, and it is now treating some two-dozen people a month in hospitals across the country.
“It’s a dream come true,” says Alka Dwivedi, an immunologist who helped to develop NexCAR19 and is now at the US National Cancer Institute (NCI) in Bethesda, Maryland. Her voice becomes tender as she describes seeing the first patient’s cancer go into remission. These are people for whom all other treatments have failed, says Dwivedi. “They are getting cured.”
“It’s very positive news,” says Renato Cunha, a haematologist at the Grupo Oncoclínicas in São Paulo, Brazil. He says the Indian product could pave the way for making advanced cellular therapies accessible to other low- and middle-income countries. “Hope is the word that comes to mind.”
The product is also a reality check for researchers in high-income countries, says Terry Fry, an immunologist and paediatric oncologist at the University of Colorado Anschutz Medical Campus in Denver, who has advised the researchers involved in setting up ImmunoACT. “It lights a little fire under all of us to look at the cost of making CAR-T cells, even in places like the United States.”
Tremendous need
CAR-T therapy involves taking someone’s blood and isolating immune components known as T cells. These are genetically modified in the laboratory to express a receptor, known as a CAR, on their surface. This helps the immune cells to find and kill cancer cells. The engineered cells are then mass-produced and infused back into the patient, in whom they proliferate and get to work.
The race to supercharge cancer-fighting T cells
Data on demand for these therapies in India are limited, but one study looking at a specific form of leukaemia found that up to 15 people in 100,000 are diagnosed with the disease, half of whom relapse within two years of receiving treatment, such as chemotherapy, and who subsequently choose palliative care1. There is a “tremendous patient need”, says Nirali Shah, a paediatric oncologist at the NCI, who is also an academic collaborator of the researchers at ImmunoACT.
NexCAR19 is similar to its US counterparts, yet distinct in key ways. Like four of the six CAR-T therapies approved by the US Food and Drug Administration (FDA), it is designed to target CD19, a marker found on B-cell cancers2. However, in existing commercial therapies, the antibody fragment at the end of a CAR is typically from mice, which limits its durability because the immune system recognizes it as foreign and eventually eliminates it. Therefore, in NexCAR19, Dwivedi and her colleagues added human proteins to the mouse antibody tips.
Lab studies showed that the ‘humanized’ CAR had comparable antitumour activity to a mouse-derived one and induced the production of lower levels of proteins called cytokines2. This is important, because some people with cancer who receive CAR-T therapy experience an extreme inflammatory reaction known as cytokine-release syndrome, which can be life-threatening.
Trial data
Early-stage clinical trials for NexCAR19 in adults with different forms of lymphoma and leukaemia, showed that in 19 of the 33 people who received the therapy, the tumours had completely disappeared at the one-month follow-up3. The tumours in another four people had shrunk by half — achieving an overall response rate of 70%. Trial participants will be followed for at least five years.
“Whether this will hold or not is something only time will tell,” says Hasmukh Jain, a medical oncologist at Tata Memorial Centre in Mumbai, who led the trials.
Natasha Kekre, a haematologist at the Ottawa Hospital, points out that the results are based on a small number of participants with a range of blood cancers, which makes it difficult to assess the treatment’s efficacy for specific cancers.
Only two of the participants experienced more severe forms of cytokine-release syndrome, and none had neurotoxicities, another common but temporary side effect of CAR-T therapy.
The safety profile is better than that of some of the FDA-approved CAR-T treatments, says Kekre. This could be related to the product, as well as to years of the scientific and medical community learning how to better care for patients, she says.
Humanizing the CAR probably contributed to the therapy’s positive safety profile, says Rahul Purwar, an immunologist at the Indian Institute of Technology Bombay, and founder of ImmunoACT. But others say that link has yet to be established.
Fry says the setting and type of patient treated in India could also affect the results. “The toxicity profile of CAR-T cells is driven by a lot of other patient factors.”
A member of the ImmunoACT team preparing the NexCAR19 cancer treatment.Credit: ImmunoACT
Slashing costs
Although the treatment’s price tag is still high for many Indians, whose annual gross national income per capita is less than $2,500, NexCAR19’s cost offers hope that CAR-T therapy can be made more cheaply in other countries and contexts. To slash costs, the team developed, tested and manufactured the product entirely in India, where labour is cheaper than in high-income countries.
To introduce CARs to T cells, researchers typically use lentiviruses, which are expensive. Purchasing enough lentiviral vector for a trial of 50 people can cost up to US$800,000 in the United States, says Steven Highfill, an immunologist at the US National Institutes of Health Clinical Center in Bethesda, who has advised the Indian team. Scientists at ImmunoACT make this gene-delivery vehicle themselves.
The Indian team also found a cheaper way to mass-produce the engineered cells, avoiding the need for expensive automated machinery, says Highfill.
Patients’ costs are further reduced by the therapy’s improved safety profile compared with some of the other FDA-approved products, Purwar says. This meant that most patients did not need to spend time in intensive-care units.
Purwar hopes to further cut costs, including by scaling up production. ImmunoACT is planning to export the therapy to Mexico, and to develop new products, including a treatment for another form of blood cancer known as multiple myeloma.
But ImmunoACT faces competition. Several other Indian companies have launched local CAR-T trials, including Immuneel Therapeutics in Bengaluru, which has licensed technology developed by Spanish academics.
Apple’s marketing chief Greg Joswiak, vice president of iPhone marketing Kaiann Drance, and a few other senior employees at the company recently participated in a ride-along interview with YouTube video creator Brian Tong.
Greg Joswiak talks with Brian Tong in a golf cart ride at Apple Park
The interview took place in a golf cart driving around Apple Park, with various employees hopping in and out to talk with Tong along the way.
Apple is widely expected to release new iPad Air and OLED iPad Pro models in the next few weeks. According to new rumors coming out of Asia, the company will announce its new iPads on Tuesday, March 26. Chinese leaker Instant Digital on Weibo this morning 日发布%23″>claimed that the date will see some sort of announcement from Apple related to new iPads, but stopped short of calling it an…
Apple’s new iPad Pro models with OLED displays will likely begin shipping to customers in April, according to information shared today by Ross Young, CEO of display industry research firm Display Supply Chain Consultants. Bloomberg’s Mark Gurman also said the new iPad Pro models might not ship until “deeper” into April in his Power On newsletter on Sunday:I’ve repeatedly said that new…
iOS 17.4.1 and iPadOS 17.4.1 should be released within the next few days, with a build number of 21E235, according to a source with a proven track record. MacRumors previously reported that Apple was internally testing iOS 17.4.1. As a minor update for the iPhone, it will likely address software bugs and/or security vulnerabilities. It is unclear if the update will include any other changes. …
The next-generation iPad Air is now reportedly shipping to the United States and other countries in preparation for launch. The rumor comes from the leaker known as “Instant Digital,” who claims that manufacturers in China are now shipping the 2024 iPad Air in two sizes to overseas locations. “Everything is ready” for launch, the Weibo user says. The sixth-generation iPad Air is rumored…
Apple’s iPhone development roadmap runs several years into the future and the company is continually working with suppliers on several successive iPhone models concurrently, which is why we sometimes get rumored feature leaks so far ahead of launch. The iPhone 17 series is no different, and already we have some idea of what to expect from Apple’s 2025 smartphone lineup. If you plan to skip…
Since Apple unveiled macOS Sonoma 14.4 on March 7, the transition to the latest software update has not been entirely smooth for everyone, and a number of issues have been reported by users that significantly impact their daily workflow. This article lists the most prominent challenges users have faced since updating to macOS Sonoma 14.4, and offers potential solutions where available. USB…
Apple suppliers will begin production of two new fourth-generation AirPods models in May, according to Bloomberg’s Mark Gurman. Based on this production timeframe, he expects the headphones to be released in September or October. Gurman expects both fourth-generation AirPods models to feature a new design with better fit, improved sound quality, and an updated charging case with a USB-C…
On Wednesday, a grand jury in South Carolina handed down an indictment against a woman who is suspected of killing a South Carolina bride in April while she was driving under the influence and collided with a golf cart that was transporting the newlyweds.
According to a copy of the indictment that has been filed against Jamie Komoroski, he was taken into custody in Charleston County on accusations of reckless homicide, felony DUI resulting in death, and two counts of felony DUI resulting in significant bodily harm. These charges were brought against him after he was accused of driving under the influence of alcohol and causing the death of another person.
Since the judge denied Komoroski’s request for bail a month ago, he has been held at the Sheriff Al Cannon Detention Center where he has been held for the past few months.
Samantha Miller, 34 years old, was killed on the night of her wedding, April 28, when a vehicle rear-ended the golf cart she was riding in. The Folly Beach Department of Public Safety made the announcement.
A statement on Aric Hutchinson’s injuries was posted on the GoFundMe website in the month of May by the groom’s family. The message stated that Hutchinson had shattered bones and suffered brain damage as a result of the tragedy.
When she crashed into the cart, Komoroski was reportedly traveling at a speed of 65 miles per hour in an area where the speed limit was 25 miles per hour. Following the incident, a toxicology study indicated that Komoroski’s blood alcohol concentration (BAC) was more than three times the permissible limit.
After the charge was brought to light on Wednesday, her attorney, Christopher Gramiccioni, declined to comment on the matter to NBC News.
When he first appeared in court, he defended Komoroski by stating that she had “zero criminal history.”